Subscribe
Date
Past
2012
2013
2014
2015
2016
2017
2018
2019
Upcoming

Dr. James Clinton is an expert at developing advanced cell biology models for the scientific community. Watch his presentation to gain an overview of the Human Cancer Models Initiative (HCMI), and of the technologies driving the development of these “next-generation” models that hold promise to transform in vitro cancer research.

  • There is an unmet need for novel preclinical cancer models that better reflect the genotype and phenotype across the spectrum of cancer found in the patient population.
  • The HCMI is funded by the National Cancer Institute, Cancer Research UK, Wellcome Sanger Institute, and the foundation Hubrecht Organoid Technology, and seeks to generate 1000 novel cancer models that will be manufactured and distributed by ATCC.
  • A wide variety of patient-derived in vitro cancer models are offered, including 3D organoids and neurospheres, as well as conditionally reprogrammed cells and other 2D models.

Expand Your Cell-based Assays With an Unlimited, Biologically Relevant Resource

Yalin Firinci, M.B.A., is adept at developing next generation biological models that incorporate primary cells. Join this webinar to hear this ATCC expert cover the following key points:

  • Differentiated iPSCs lend the ability to run large toxicity studies and drug screens on highly biologically relevant cells.
  • ATCC iPSCs were used as the source for three types of differentiated cells: CD34+ progenitors, mesenchymal stem cells (MSCs), and monocytes.
  • ATCC R&D scientists have generated in-depth data showing the iPSC-derived cells can be incorporated into immunoassays and further differentiated into cell types such as osteocytes, chondrocytes, and adipocytes.